New life-changing treatment option fenfluramine recommended for type of rare epilepsy, Lennox–Gastaut syndrome ...

Final NICE guidance recommends lisocabtagene maraleucel (also called liso-cel or Breyanzi and made by Bristol Myers Squibb) as an option for treating people with large B-cell lymphoma ...

Draft guidance published for an immunotherapy treatment that could prevent blood cancer from returning in adults who've ...

We’ve partnered with the USA-based Institute for Clinical and Economic Review (ICER) and the Canadian Drug Agency (CDA-AMC) ...

Evidence-based recommendations on selpercatinib (Retsevmo) for treating RET fusion-positive advanced non-small-cell lung cancer (NSCLC) that has not been treated with a RET inhibitor in adults. This ...

Selpercatinib (Retsevmo, Eli Lilly) as monotherapy is indicated for 'the treatment of adults with advanced RET fusion-positive non-small cell lung cancer (NSCLC) not previously treated with a RET ...

Tools to help you put the guidance into practice.

The National Institute for Health and Care Excellence (NICE) is producing late-stage assessment guidance on Drug-eluting coronary stents for treating coronary artery disease: late-stage assessment.

This topic was considered by the lead team of the highly specialised technologies committee, which includes the chair and vice chair. Committee members are asked to declare any interests in the ...

The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D. Committee members are asked to declare any interests in the technology being ...